The United States continues to face a public health crisis of opioid-related harm, the effects of which could be dramatically reduced through increased access to opioid agonist therapy with the medications methadone and buprenorphine. Despite overwhelming evidence of their efficacy, unduly restrictive federal, state, and local regulation significantly impedes access to these life-saving medications. This commentary outlines immediate, concrete steps that federal, state, and local governments can take to change law from barrier to facilitator of evidence-based treatment for opioid use disorder.
Recent Abstracts
Information About New Federal Regulations for Opioid Treatment Programs (OTPs)
Centering Country Ownership and Leadership: The Data for Health Initiative’s Approach
Mass Media Campaigns
Data for Health: Advancing Gender Equity
The Index of Tobacco Control Sustainability
Index of Tobacco Control Sustainability (ITCS): India Subnational Tobacco Control
Index of Tobacco Control Sustainability (ITCS): Indonesia Subnational Tobacco Control
Considerations for Planning Childhood Blood Lead Surveillance
Air Quality Monitoring Toolkit: Assessing Second-Hand Smoke in Hospitality Venues
Association between high-threshold practices and buprenorphine treatment termination